LMNL
(NASDAQ)
4.14
+0.17   (+4.28%)
After Hours: 4.17 +0.0300 (+0.72%)
Volume (24h) Market Cap. Day Range 52w Range
383.01K 121.36M 3.91 - 4.18 3.51 - 31.45
Nov-24-20 10:00AM /R E P E A T -- Notice to the media - COVID-19 Update (November 24, 2020) - Ministers and Government of Canada officials to hold a news conference on coronavirus disease/CNW Group
Nov-23-20 07:00AM Invitation to media - Élisabeth Brière, Parliamentary Secretary to Minister Mélanie Joly, to announce Government of Canada support for AMP DrummondCNW Group
Nov-13-20 09:20AM Liminal Biosciences to Present at The Stifel Virtual Healthcare ConferenceCNW Group
Nov-12-20 04:57AM Liminal BioSciences Reports Third Quarter Financial ResultsPR Newswire
Nov-10-20 06:33AM Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference CallCNW Group
Nov-08-20 07:01AM Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLAPR Newswire
Nov-06-20 09:26AM Liminal Biosciences To Report Q3 2020 Results And Hold Conference CallPR Newswire
Nov-05-20 04:35AM Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and ExpositionCNW Group
Oct-30-20 08:30AM Liminal BioSciences Announces Private Placement Financing of USD$30 MillionPR Newswire
Oct-07-20 09:30AM Canada and Nova Scotia invest in a new community centre for Sheet HarbourCNW Group
Sep-21-20 08:16AM Liminal BioSciences Provides Update on Progress on BLA for Ryplazim®(plasminogen)PR Newswire
Sep-09-20 08:00AM Liminal BioSciences to Present at The H.C. Wainwright 22nd Annual Global Investment ConferencePR Newswire
Sep-08-20 06:00AM Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen) for Treatment of Congenital Plasminogen DeficiencyPR Newswire
Sep-01-20 08:43AM Germany Economics Ministry Says Corona Recovery Well UnderwayCNW Group
08:36AM Liminal BioSciences Announces New Appointments to its Board of DirectorsPR Newswire
Aug-24-20 01:30AM Trump Announces Authorization of Blood Plasma Covid Treatment. The Only Hitch: It Might Not Work.Barrons.com
10:03AM Price Over Earnings Overview: Liminal BiosciencesBenzinga
Aug-10-20 05:01AM Liminal BioSciences reports financial results for Q2-2020PR Newswire
Aug-06-20 05:01AM Liminal Biosciences to Present at Canaccord 40th Annual Growth ConferencePR Newswire
Jul-22-20 07:55AM Liminal BioSciences to Voluntarily Delist from the Toronto Stock ExchangePR Newswire
Jul-17-20 08:00AM Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven DiseasesPR Newswire
Jul-02-20 11:16AM Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 TherapyCNW Group
Jun-30-20 05:31AM Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered DonorsPR Newswire
05:00AM Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020CNW Group
Jun-11-20 05:00AM Liminal BioSciences to Present at Raymond James Human Health Innovation ConferenceCNW Group
Jun-09-20 03:53AM Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM)CNW Group
May-28-20 05:30AM Liminal BioSciences to present at Jefferies Virtual Healthcare ConferenceCNW Group
May-22-20 07:14AM Investors Who Bought Liminal BioSciences (TSE:LMNL) Shares Five Years Ago Are Now Down 100%Simply Wall St.
May-13-20 05:00AM Liminal Biosciences Reports Q1 2020 ResultsCNW Group
Mar-23-20 06:30AM Liminal BioSciences, Inc. to Host Earnings CallACCESSWIRE
Mar-22-20 03:23AM Liminal BioSciences comments on Coronavirus (COVID-19)PR Newswire
Mar-20-20 05:01AM Liminal Biosciences Reports Fourth Quarter and 2019 Year End ResultsPR Newswire
05:00AM Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcastPR Newswire
Feb-12-20 07:30AM Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone SymposiaPR Newswire
Feb-06-20 07:30AM Liminal BioSciences announces upcoming investor presentation at BIO CEO & Investor ConferenceCNW Group
Jan-13-20 07:00AM Liminal BioSciences Outlines Corporate Priorities for 2020PR Newswire
Dec-23-19 03:43AM Liminal BioSciences Comments on Unusual Market ActivityCNW Group
Nov-28-19 04:40AM AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019CNW Group
Nov-27-19 07:30AM Liminal BioSciences to Present at Piper Jaffray Healthcare ConferencePR Newswire
Nov-25-19 12:03PM Liminal BioSciences announces closing of divestiture of bioseparations division to KKRCNW Group
Nov-18-19 07:30AM Liminal Biosciences announces effectiveness of Registration Statement on Form F-10 and filing of Prospectus SupplementCNW Group
Liminal BioSciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The Bioseparations segment develops and manufactures affinity absorbents and Mimetic Ligand purification platform that are used by pharmaceutical and medical companies for extraction and purification manufacturing processes. In addition, it develops processes to recover and purify various other proteins from plasma, including intravenous immunoglobulin, inter-alpha-inhibitor-proteins, fibrinogen, alpha1 antitrypsin, and C1 esterase inhibitor. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Cap:    |  Volume (24h):